Page 43 - TD-4-1

Tumor Discovery CDK4/6 inhibitor resistance in breast cancer

Biol. 2023;11:1148792. 2024;155(12):2211-2222.
doi: 10.3389/fcell.2023.1148792 doi: 10.1002/ijc.35126.
22. Wander SA, Cohen O, Gong X, et al. The genomic 32. Davis AA, Luo J, Zheng T, et al. Genomic complexity predicts
landscape of intrinsic and acquired resistance to cyclin- resistance to endocrine therapy and CDK4/6 inhibition in
dependent kinase 4/6 inhibitors in patients with hormone hormone receptor-positive (HR+)/HER2-negative metastatic
receptor-positive metastatic breast cancer. Cancer Discov. breast cancer. Clin Cancer Res. 2023;29(9):1719-1729.
2020;10(8):1174-1193.
doi: 10.1158/1078-0432.CCR-22-2177.
doi: 10.1158/2159-8290.CD-19-1390
33. Li Z, Zou W, Zhang J, et al. Mechanisms of CDK4/6 inhibitor
23. Lelliott EJ, Sheppard KE, McArthur GA. Harnessing resistance in luminal breast cancer. Front Pharmacol.
the immunotherapeutic potential of CDK4/6 inhibitors 2020;11:580251.
in melanoma: Is timing everything? NPJ Precis Oncol. doi: 10.3389/fphar.2020.580251
2022;6(1):26.
34. Yoshida A, Lee EK, Diehl JA. Induction of therapeutic
doi: 10.1038/s41698-022-00273-9
senescence in vemurafenib-resistant melanoma by extended
24. Sun M, Dong L, Wang Y, et al. The role of targeting CDK4/6 in inhibition of CDK4/6. Cancer Res. 2016;76(10):2990-3002.
cancer immunotherapy. Holistic Integr Oncol. 2024;3(1):32.
doi: 10.1158/0008-5472.CAN-15-2931
doi: 10.1007/s44178-024-00100-0
35. Hirai N, Hatanaka Y, Hatanaka KC, et al. Cyclin-dependent
25. Teh JLF, Aplin AE. Arrested developments: CDK4/6 kinase 4 upregulation mediates acquired resistance of
inhibitor resistance and alterations in the tumor immune dabrafenib plus trametinib in BRAF V600E-mutated lung
microenvironment. Clin Cancer Res. 2019;25(3):921-927. cancer. Transl Lung Cancer Res. 2021;10(9):3737-3744.
doi: 10.1158/1078-0432.CCR-18-1967 doi: 10.21037/tlcr-21-415

26. Deng J, Wang ES, Jenkins RW, et al. CDK4/6 inhibition 36. Nassar KW, Hintzsche JD, Bagby SM, et al. Targeting
augments antitumor immunity by enhancing T-cell CDK4/6 represents a therapeutic vulnerability in acquired
activation. Cancer Discov. 2018;8(2):216-233. BRAF/MEK inhibitor-resistant melanoma. Mol Cancer
Ther. 2021;20(10):2049-2060.
doi: 10.1158/2159-8290.CD-17-0915
doi: 10.1158/1535-7163.MCT-20-1126
27. Chin YM, Shibayama T, Chan HT, et al. Serial circulating
tumor DNA monitoring of CDK4/6 inhibitors response in 37. Lelliott EJ, McArthur GA, Oliaro J, Sheppard KE.
metastatic breast cancer. Cancer Sci. 2022;113(5):1808-1820. Immunomodulatory effects of BRAF, MEK, and CDK4/6
inhibitors: Implications for combining targeted therapy
doi: 10.1111/cas.15304
and immune checkpoint blockade for the treatment of
28. Krasniqi E, Goeman F, Pulito C, et al. Biomarkers of response melanoma. Front Immunol. 2021;12:661737.
and resistance to CDK4/6 inhibitors in breast cancer: Hints
from liquid biopsy and microRNA exploration. Int J Mol Sci. doi: 10.3389/fimmu.2021.661737
2022;23(23):14534. 38. Cheng K, Zhou Z, Chen Q, et al. CDK4/6 inhibition
sensitizes MEK inhibition by inhibiting cell cycle and
doi: 10.3390/ijms232314534
proliferation in pancreatic ductal adenocarcinoma. Sci
29. Goetz MP, Hamilton EP, Campone M, et al. Landscape of Rep. 2024;14(1):8389.
baseline and acquired genomic alterations in circulating
tumor DNA with abemaciclib alone or with endocrine doi: 10.1038/s41598-024-57417-z
therapy in advanced breast cancer. Clin Cancer Res. 39. Sonke GS, van Ommen-Nijhof A, Wortelboer N, et al. Early
2024;30(10):2233-2244. versus deferred use of CDK4/6 inhibitors in advanced breast
cancer. Nature. 2024;636:474-480.
doi: 10.1158/1078-0432.CCR-22-3573
doi: 10.1038/s41586-024-08035-2
30. Asghar US, Kanani R, Roylance R, Mittnacht S. Systematic
review of molecular biomarkers predictive of resistance to 40. Wells CI, Vasta JD, Corona CR, et al. Quantifying
CDK4/6 inhibition in metastatic breast cancer. JCO Precis CDK inhibitor selectivity in live cells. Nat Commun.
Oncol. 2022;6:e2100002. 2020;11(1):2743.
doi: 10.1200/PO.21.00002 doi: 10.1038/s41467-020-16559-0
31. Kindt CK, Alves CL, Ehmsen S, et al. Genomic alterations 41. Bidard FC, Hardy-Bessard AC, Dalenc F, et al. Switch to
associated with resistance and circulating tumor DNA fulvestrant and palbociclib versus no switch in advanced
dynamics for early detection of progression on CDK4/6 breast cancer with rising ESR1 mutation during aromatase
inhibitor in advanced breast cancer. Int J Cancer. inhibitor and palbociclib therapy (PADA-1): A randomised,

Volume 4 Issue 1 (2025) 35 doi: 10.36922/td.7107